Vertex’s Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis
The prize honors the groundbreaking work of Dr. Negulescu and the entire Vertex team who discovered and developed the first and only approved medicines that address the underlying cause of CF. Vertex has brought three transformative CF medicines to patients in the last six years, and has a pipeline of investigational CF medicines that have the potential to treat 90% of people with this devastating disease.
“It took the work of hundreds of people at Vertex across research, development, regulatory, and commercial to get these medicines from discovery to patients, and this award recognizes all of that hard work and dedication,” said Dr. Negulescu. “We have made great progress, but there are still more patients that need our help. So, we have more work to do.”
This year’s recipients represent the major scientific inflection points
in the modern history of CF – from the discovery of the genetic
mutations that cause CF all the way through the first
The Warren Alpert Foundation Prize is awarded annually to individuals
whose scientific achievements have led to the prevention, cure or
treatment of human diseases or disorders, and/or whose research
constitutes a seminal scientific finding that holds great promise of
ultimately changing our understanding of/or ability to treat disease. A
symposium will be hosted at
For more information visit the Warren Alpert Foundation Prize website: https://warrenalpert.org/
To read a Q&A with Dr. Negulescu about the Vertex team’s work in CF over the last 20 years, click here.
About Cystic Fibrosis
Cystic fibrosis is a rare, life-threatening genetic disease affecting
approximately 75,000 people in
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in
For additional information and the latest updates from the company, please visit www.vrtx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180621006222/en/
Vertex Pharmaceuticals Incorporated
Michael Partridge, 617-341-6108
Eric Rojas, 617-961-7205
Zach Barber, 617-341-6470
Heather Nichols, 617-341-6992
Europe & Australia:
Rebecca Hunt, +44 7718 962 690